China Sky One Medical Issues Financial Guidance for Third Quarter 2007
For the third quarter 2007, the Company anticipates revenue to increase109% to approximately USD$14.0 million from USD$6.7 million in the same periodof 2006. Gross margin is expected to improve substantially to 77%, compared to67% in the third quarter of 2006.The Company's third quarter 2007 revenue and gross margin forecasts are basedon projected growth in the following areas/segments:
These forecasts reflect the Company's current and preliminary view, whichis subject to change.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding companywhose principal operations are through its subsidiaries, which are engaged inthe manufacturing, marketing and distribution of pharmaceutical, medicinal anddiagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian DiRen Medical Science and Technology Company ("TDR") and Harbin First Bio-Engineering Company Limited ("First"), the Company's principal revenue sourceis the manufacture and sale of over-the- counter pharmaceutical products.http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities LitigationReform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should,""project," "plan," "seek," "intend," or "anticipate" or the negative thereofor comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingour future plans, objectives or performance. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.-- Sales growth of the Company's proprietary product line -- Sales of other manufactured brands through the Company's expanding distribution network -- Export sales of the Company's product, the Slim Patch
SOURCE China Sky One Medical, Inc.
You May Also Like